 The good news is the early conclusion of a trial of a preventive treatment called lenacapavir, reporting early because the statistics from the trial showed it was so good at protecting young women from infection. The approach is what they call PREP, pre-exposure prophylaxis, normally a daily regimen of pills in sexually active people, but in this case an injectable taken just twice a year.